Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Dose Ranging Multi-Centre, Single Blind, Parallel-Group, Controlled Study of the Safety, Tolerability and Immunogenicity of Recombinant (rPA Based) Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed in a Healthy Population

NCT00170469 is registered in ClinicalTrials.gov with PharmAthene UK Limited as lead sponsor.

NCT NCT00170469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00170469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Dose Ranging Multi-Centre, Single Blind, Parallel-Group, Controlled Study of the Safety, Tolerability and Immunogenicity of Recombinant (rPA Based) Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed in a Healthy Population
Lead sponsor
PharmAthene UK Limited
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2005
Completion date
February 28, 2007
Enrollment
226 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

bacillus anthracis (anthrax)